Disclosures: Brett McGettigan: Nothing to Disclose, Dawood Al Dawood: Nothing to Disclose, Harmeet Malhi: MERCK: Consultant, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor 1569 HEPATIC METHYLTRANSFERASE PROTEINS MEDIATE PNPLA3-I148M-DRIVEN LIPID DROPLET DYNAMICS IN FATTY LIVER Xinshou Ouyang 1 Yan Zhang 2 Suyavaran ARUMUGAM 2 Shi-Ying Cai 1 Wanqing Liu 3 Wajahat Mehal 1 , 1 Yale University, 2 Yale School of Medicine, 3 Wayne State University Background: The accumulation of Lipid droplets (LDs) characterizes fatty liver in metabolic dysfunction-associated fatty liver disease (MAFLD) and alcohol-associated liver disease (ALD), closely tied to genetic variants, particularly PNPLA3 -I148M
Seeley, consults for GLP-1 drugmakers
Apart from DYRK inhibitors, other compounds like allarline, gonadotropin-releasing hormone receptor agonist, and AZD7687, diacylglycerol acyltransferase 1 inhibitor, increase the number of L and K cells in zebrafish [205]
Reduces risk of cardiovascular complications in patients with diabetes (under ongoing study)
